Brief: Lonza Group Confirms Full Year 2025 Outlook For CDMO And CHI Businesses

Lonza AG

23/10/2025 06:36

Oct 23 (Reuters) - LONZA GROUP AG LONN.S:

LONZA DELIVERS A STRONG Q3 2025 AND CONFIRMS FULL-YEAR 2025 OUTLOOK FOR ITS CDMO AND CHI BUSINESSES

CDMO OUTLOOK FOR FULL-YEAR 2025 CONFIRMED: UPGRADED AT HALF-YEAR TO CER SALES GROWTH OF 20-21% AND A CORE EBITDA MARGIN OF 30-31%

LARGE CONTRACT SIGNINGS IN Q3, INCLUDING ANOTHER SIGNIFICANT COMMERCIAL CONTRACT FOR VACAVILLE

EXPECTS NO FINANCIAL IMPACT FROM US TRADE POLICIES

CAPSULES & HEALTH INGREDIENTS (CHI) RETURNED TO GROWTH AS EXPECTED AND IN LINE WITH FULL-YEAR OUTLOOK

STRONG MOMENTUM IN INTEGRATED BIOLOGICS BASED ON CONTINUING ROBUST DEMAND FOR LARGE-SCALE MAMMALIAN ASSETS, FURTHER SUPPORTED BY VACAVILLE (US) ACQUISITION

FULL-YEAR 2025 PERFORMANCE IS EXPECTED TO REMAIN MODERATE IN CONTEXT OF SOFTER H1

CHI'S STRONG MANUFACTURING PRESENCE IN US IS CONTINUING TO SUPPORT CUSTOMERS IN NAVIGATING EVOLVING US TARIFF ENVIRONMENT

IN 2025, LONZA EXPECTS A HEALTHY LEVEL OF CONTRACT SIGNINGS ACROSS TECHNOLOGIES AND SITES WITHIN ITS CDMO BUSINESS

FURTHER SIGNINGS IN VACAVILLE ARE EXPECTED IN COMING MONTHS

EXPECTS NO MATERIAL FINANCIAL IMPACT FROM CURRENTLY ANNOUNCED US TRADE POLICIES

Further company coverage: LONN.S

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))